BE1022355B1 - Nouvelles méthodes d'induction d'une réponse immunitaire - Google Patents

Nouvelles méthodes d'induction d'une réponse immunitaire Download PDF

Info

Publication number: BE1022355B1
Authority: BE; Belgium
Prior art keywords: adjuvant; composition; rts; times lower; antigen
Prior art date: 2014-04-02

Application number

BE2015/5209A

Other languages

English (en)

French (fr)

Other versions

BE1022355A1 (fr

Inventor

William Ripley Ballou Jr

Arnaud Michel Didierlaurent

Der Most Robbert Gerrit Van

Original Assignee

Glaxosmithkline Biologicals S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-02

Filing date

2015-04-02

Publication date

2016-03-26

2015-04-02 Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.

2016-02-16 Publication of BE1022355A1 publication Critical patent/BE1022355A1/fr

2016-03-26 Application granted granted Critical

2016-03-26 Publication of BE1022355B1 publication Critical patent/BE1022355B1/fr

Links

238000000034 method Methods 0.000 title claims abstract description 71
230000028993 immune response Effects 0.000 title claims abstract description 22
230000001939 inductive effect Effects 0.000 title claims description 18
239000000203 mixture Substances 0.000 claims abstract description 164
239000002671 adjuvant Substances 0.000 claims abstract description 152
230000002163 immunogen Effects 0.000 claims abstract description 74
239000000427 antigen Substances 0.000 claims description 102
102000036639 antigens Human genes 0.000 claims description 102
108091007433 antigens Proteins 0.000 claims description 102
150000007949 saponins Chemical class 0.000 claims description 34
229930182490 saponin Natural products 0.000 claims description 33
239000000556 agonist Substances 0.000 claims description 32
239000001397 quillaja saponaria molina bark Substances 0.000 claims description 28
102000002689 Toll-like receptor Human genes 0.000 claims description 20
108020000411 Toll-like receptor Proteins 0.000 claims description 20
201000004792 malaria Diseases 0.000 claims description 16
238000002360 preparation method Methods 0.000 claims description 16
241000282412 Homo Species 0.000 claims description 14
101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 14
102100039360 Toll-like receptor 4 Human genes 0.000 claims description 14
239000012634 fragment Substances 0.000 claims description 13
239000002245 particle Substances 0.000 claims description 13
241000282414 Homo sapiens Species 0.000 claims description 9
239000007764 o/w emulsion Substances 0.000 claims description 9
241000223960 Plasmodium falciparum Species 0.000 claims description 8
229930182558 Sterol Natural products 0.000 claims description 8
150000003432 sterols Chemical class 0.000 claims description 8
235000003702 sterols Nutrition 0.000 claims description 8
101710117490 Circumsporozoite protein Proteins 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 5
241000224016 Plasmodium Species 0.000 claims description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
229910052782 aluminium Inorganic materials 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
239000000839 emulsion Substances 0.000 claims description 2
241000223810 Plasmodium vivax Species 0.000 claims 1
102000004169 proteins and genes Human genes 0.000 description 34
108090000623 proteins and genes Proteins 0.000 description 34
150000001413 amino acids Chemical class 0.000 description 27
235000017709 saponins Nutrition 0.000 description 27
229960005486 vaccine Drugs 0.000 description 27
239000002502 liposome Substances 0.000 description 15
150000002632 lipids Chemical class 0.000 description 9
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
210000003046 sporozoite Anatomy 0.000 description 8
241000700721 Hepatitis B virus Species 0.000 description 7
101710137302 Surface antigen S Proteins 0.000 description 7
230000003053 immunization Effects 0.000 description 7
238000002649 immunization Methods 0.000 description 7
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 7
240000009188 Phyllostachys vivax Species 0.000 description 6
210000004207 dermis Anatomy 0.000 description 6
-1 glucopyranosyl lipid Chemical class 0.000 description 6
YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 6
150000003904 phospholipids Chemical class 0.000 description 6
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000002255 vaccination Methods 0.000 description 5
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
210000002615 epidermis Anatomy 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
244000045947 parasite Species 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 3
241000725619 Dengue virus Species 0.000 description 3
241000255925 Diptera Species 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
238000011161 development Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
210000003491 skin Anatomy 0.000 description 3
OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 2
CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 description 2
YFWHNAWEOZTIPI-DIPNUNPCSA-N 1,2-dioctadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCCCC YFWHNAWEOZTIPI-DIPNUNPCSA-N 0.000 description 2
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
101000993654 Escherichia coli (strain K12) Pantothenate kinase Proteins 0.000 description 2
101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
101000983333 Plasmodium falciparum (isolate NF54) 25 kDa ookinete surface antigen Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
102100024333 Toll-like receptor 2 Human genes 0.000 description 2
102100039390 Toll-like receptor 7 Human genes 0.000 description 2
208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
SNKAWJBJQDLSFF-YEUCEMRASA-N [2-({2,3-bis[(9z)-octadec-9-enoyloxy]propyl phosphonato}oxy)ethyl]trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-YEUCEMRASA-N 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000004873 anchoring Methods 0.000 description 2
230000000078 anti-malarial effect Effects 0.000 description 2
239000003430 antimalarial agent Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000007933 dermal patch Substances 0.000 description 2
229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 2
230000004927 fusion Effects 0.000 description 2
150000002327 glycerophospholipids Chemical class 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
229940124735 malaria vaccine Drugs 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229940042880 natural phospholipid Drugs 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical group 0.000 description 2
230000003252 repetitive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
BIABMEZBCHDPBV-BEBVUIBBSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-BEBVUIBBSA-N 0.000 description 1
MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
OZSITQMWYBNPMW-GDLZYMKVSA-N 1,2-ditetradecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCC OZSITQMWYBNPMW-GDLZYMKVSA-N 0.000 description 1
PAZGBAOHGQRCBP-HGWHEPCSSA-N 1-hexadecanoyl-2-[(9Z)-octadec-9-enoyl]-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-HGWHEPCSSA-N 0.000 description 1
PAZGBAOHGQRCBP-DDDNOICHSA-N 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-DDDNOICHSA-N 0.000 description 1
KQPKMEYBZUPZGK-UHFFFAOYSA-N 4-[(4-azido-2-nitroanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CC1=NC=C(CO)C(CNC=2C(=CC(=CC=2)N=[N+]=[N-])[N+]([O-])=O)=C1O KQPKMEYBZUPZGK-UHFFFAOYSA-N 0.000 description 1
101150116940 AGPS gene Proteins 0.000 description 1
102100031675 DnaJ homolog subfamily C member 5 Human genes 0.000 description 1
101710204837 Envelope small membrane protein Proteins 0.000 description 1
DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
108010000916 Fimbriae Proteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241000606768 Haemophilus influenzae Species 0.000 description 1
101001111984 Homo sapiens N-acylneuraminate-9-phosphatase Proteins 0.000 description 1
101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
ULNXMMYXQKGNPG-LPEHRKFASA-N Met-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N ULNXMMYXQKGNPG-LPEHRKFASA-N 0.000 description 1
241001092142 Molina Species 0.000 description 1
102100023906 N-acylneuraminate-9-phosphatase Human genes 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001505483 Plasmodium falciparum 3D7 Species 0.000 description 1
YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 1
102000029301 Protein S Human genes 0.000 description 1
108010066124 Protein S Proteins 0.000 description 1
229940096437 Protein S Drugs 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
108700005482 Protozoan circumsporozoite Proteins 0.000 description 1
241001454523 Quillaja saponaria Species 0.000 description 1
235000009001 Quillaja saponaria Nutrition 0.000 description 1
101001000212 Rattus norvegicus Decorin Proteins 0.000 description 1
101710088839 Replication initiation protein Proteins 0.000 description 1
229940124614 TLR 8 agonist Drugs 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 1
102100039357 Toll-like receptor 5 Human genes 0.000 description 1
102100033110 Toll-like receptor 8 Human genes 0.000 description 1
102100033117 Toll-like receptor 9 Human genes 0.000 description 1
HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
CBUTVEZRFBQJMO-WJOKGBTCSA-N [(2R)-2,3-dihydroxypropyl] 2-[di(tetradecanoyl)amino]ethyl hydrogen phosphate Chemical compound C(CCCCCCCCCCCCC)(=O)N(CCOP(OC[C@@H](CO)O)(=O)O)C(CCCCCCCCCCCCC)=O CBUTVEZRFBQJMO-WJOKGBTCSA-N 0.000 description 1
FVJZSBGHRPJMMA-DHPKCYQYSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-DHPKCYQYSA-N 0.000 description 1
BPHQZTVXXXJVHI-IADGFXSZSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-IADGFXSZSA-N 0.000 description 1
YGPZYYDTPXVBRA-RTDBHSBRSA-N [(2r,3s,4r,5r,6s)-2-[[(2r,3r,4r,5s,6r)-3-[[(3r)-3-dodecanoyloxytetradecanoyl]amino]-6-(hydroxymethyl)-5-phosphonooxy-4-[(3r)-3-tetradecanoyloxytetradecanoyl]oxyoxan-2-yl]oxymethyl]-3,6-dihydroxy-5-[[(3r)-3-hydroxytetradecanoyl]amino]oxan-4-yl] (3r)-3-hydr Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](O)O1 YGPZYYDTPXVBRA-RTDBHSBRSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
229940076810 beta sitosterol Drugs 0.000 description 1
NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
239000011246 composite particle Substances 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 description 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000008029 eradication Effects 0.000 description 1
229960002061 ergocalciferol Drugs 0.000 description 1
DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000008271 glucosaminides Chemical class 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229940090046 jet injector Drugs 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000035515 penetration Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000009522 phase III clinical trial Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
244000000040 protozoan parasite Species 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
229950005143 sitosterol Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
150000003408 sphingolipids Chemical class 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
238000010186 staining Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
229940032091 stigmasterol Drugs 0.000 description 1
235000016831 stigmasterol Nutrition 0.000 description 1
BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000000434 stratum corneum Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
235000001892 vitamin D2 Nutrition 0.000 description 1
239000011653 vitamin D2 Substances 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Tropical Medicine & Parasitology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BE2015/5209A 2014-04-02 2015-04-02 Nouvelles méthodes d'induction d'une réponse immunitaire BE1022355B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB1405921.6		2014-04-02
GBGB1405921.6A GB201405921D0 (en)	2014-04-02	2014-04-02	Novel methods for inducing an immune response

Publications (2)

Publication Number	Publication Date
BE1022355A1 BE1022355A1 (fr)	2016-02-16
BE1022355B1 true BE1022355B1 (fr)	2016-03-26

Family

ID=50737873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2015/5209A BE1022355B1 (fr)	2014-04-02	2015-04-02	Nouvelles méthodes d'induction d'une réponse immunitaire

Country Status (18)

Country	Link
US (3)	US10688168B2 (2)
EP (2)	EP3125929B8 (2)
JP (2)	JP6645982B2 (2)
KR (2)	KR20160132115A (2)
CN (2)	CN106456739A (2)
AR (1)	AR099960A1 (2)
AU (1)	AU2015239025B2 (2)
BE (1)	BE1022355B1 (2)
BR (2)	BR112016022463A2 (2)
CA (2)	CA2943007C (2)
EA (1)	EA037405B1 (2)
ES (2)	ES2853773T3 (2)
GB (1)	GB201405921D0 (2)
IL (1)	IL247493B (2)
MX (3)	MX2016012982A (2)
SG (1)	SG11201607086QA (2)
WO (2)	WO2015150567A1 (2)
ZA (1)	ZA201605955B (2)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201405921D0 (en) *	2014-04-02	2014-05-14	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response
GB201621686D0 (en) *	2016-12-20	2017-02-01	Glaxosmithkline Biologicals Sa	Novel methods for inducing an immune response
CA3063954A1 (en)	2017-05-30	2018-12-06	Glaxosmithline Biologicals S.A.	Methods for manufacturing an adjuvant
BR112020010790A2 (pt)	2017-12-01	2020-11-10	Glaxosmithkline Biologicals S.A.	purificação da saponina
JP7640473B2 (ja)	2019-06-05	2025-03-05	グラクソスミスクラインバイオロジカルズソシエテアノニム	サポニン精製
KR20230013237A (ko)	2020-03-09	2023-01-26	다이나박스 테크놀로지 코퍼레이션	Tlr9 효능제를 포함하는 대상포진 백신
CN113125756B (zh) *	2020-07-15	2022-10-25	南京岚煜生物科技有限公司	抗体标准品赋值和抗原中和当量确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US152200A (en) *		1874-06-16		Improvement in garters
US1002607A (en) *	1905-08-28	1911-09-05	John Willard Taylor	Paper pulley.
UA56132C2 (uk) *	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2502268A1 (en)	2002-10-23	2004-05-06	Glaxosmithkline Biologicals S.A.	Methods for vaccinating against malaria
ES2371175T3 (es)	2004-10-14	2011-12-28	Crucell Holland B.V.	Vacunas de sensibilización/refuerzo de malaria.
EP2426141B1 (en) *	2005-04-29	2014-10-01	GlaxoSmithKline Biologicals S.A.	Method for preventing or treating M tuberculosis infection
TWI457133B (zh) *	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
CA2668100C (en) *	2006-11-01	2014-12-23	Immport Therapeutics, Inc.	Compositions and methods for immunodominant antigens
HRP20161606T1 (hr) *	2007-03-02	2017-01-13	Glaxosmithkline Biologicals Sa	Novi postupak i pripravci
US9452209B2 (en) *	2007-04-20	2016-09-27	Glaxosmithkline Biologicals Sa	Influenza vaccine
MX2011000982A (es) *	2008-07-25	2011-03-02	Glaxosmithkline Biolog Sa	La proteina de tuberculosis rv2386c, composiciones y usos de la misma.
PT2315773T (pt) *	2008-07-25	2016-11-23	Glaxosmithkline Biologicals Sa	Polipéptidos, polinucleótidos e composições para utilização no tratamento de tuberculose latente
HUE037121T2 (hu) *	2008-07-25	2018-08-28	Glaxosmithkline Biologicals Sa	Új készítmények és eljárások
SI2528621T1 (sl) *	2010-01-27	2017-01-31	Glaxosmithkline Biologicals S.A.,	Modificirani tuberkolozni antigeni
PL2651436T3 (pl) *	2010-12-14	2016-10-31		Kompozycja antygenów mykobakteryjnych
US20170056345A1 (en) *	2014-02-18	2017-03-02	Stc.Unm	Booster drug therapy for mycobacterium infections
GB201405921D0 (en) *	2014-04-02	2014-05-14	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response
WO2015161853A1 (en) *	2014-04-24	2015-10-29	Statens Serum Institut	New m.tuberculosis vaccines
GB201513176D0 (en) *	2015-07-27	2015-09-09	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response

2014
- 2014-04-02 GB GBGB1405921.6A patent/GB201405921D0/en not_active Ceased
2015
- 2015-04-02 CN CN201580030331.2A patent/CN106456739A/zh active Pending
- 2015-04-02 CA CA2943007A patent/CA2943007C/en active Active
- 2015-04-02 WO PCT/EP2015/057423 patent/WO2015150567A1/en not_active Ceased
- 2015-04-02 EP EP15713532.8A patent/EP3125929B8/en active Active
- 2015-04-02 BE BE2015/5209A patent/BE1022355B1/fr not_active IP Right Cessation
- 2015-04-02 MX MX2016012982A patent/MX2016012982A/es unknown
- 2015-04-02 CA CA2943711A patent/CA2943711A1/en not_active Abandoned
- 2015-04-02 BR BR112016022463A patent/BR112016022463A2/pt not_active Application Discontinuation
- 2015-04-02 JP JP2016559965A patent/JP6645982B2/ja active Active
- 2015-04-02 EP EP15713531.0A patent/EP3125930B1/en active Active
- 2015-04-02 SG SG11201607086QA patent/SG11201607086QA/en unknown
- 2015-04-02 AU AU2015239025A patent/AU2015239025B2/en active Active
- 2015-04-02 US US15/300,852 patent/US10688168B2/en active Active
- 2015-04-02 ES ES15713531T patent/ES2853773T3/es active Active
- 2015-04-02 MX MX2016012932A patent/MX2016012932A/es unknown
- 2015-04-02 US US15/300,338 patent/US10624961B2/en active Active
- 2015-04-02 CN CN201580016665.4A patent/CN106456738B/zh active Active
- 2015-04-02 KR KR1020167029523A patent/KR20160132115A/ko not_active Ceased
- 2015-04-02 JP JP2016560336A patent/JP6655549B2/ja not_active Expired - Fee Related
- 2015-04-02 BR BR112016022787-5A patent/BR112016022787A2/pt not_active Application Discontinuation
- 2015-04-02 ES ES15713532T patent/ES2961840T3/es active Active
- 2015-04-02 KR KR1020237017095A patent/KR102762440B1/ko active Active
- 2015-04-02 IL IL247493A patent/IL247493B/en unknown
- 2015-04-02 WO PCT/EP2015/057424 patent/WO2015150568A1/en not_active Ceased
- 2015-04-02 EA EA201691638A patent/EA037405B1/ru not_active IP Right Cessation
- 2015-04-06 AR ARP150101025A patent/AR099960A1/es unknown
2016
- 2016-08-26 ZA ZA2016/05955A patent/ZA201605955B/en unknown
- 2016-09-30 MX MX2022013912A patent/MX2022013912A/es unknown
2020
- 2020-03-11 US US16/815,635 patent/US11951161B2/en active Active

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ELENA MATA ET AL: "Malaria Vaccine Adjuvants: Latest Update and Challenges in Preclinical and Clinical Research", BIOMED RESEARCH INTERNATIONAL, vol. 6, no. 5, 1 January 2013 (2013-01-01), pages 599 - 19, XP055208483, ISSN: 2314-6133, DOI: 10.1016/j.ijpharm.2008.08.039 *
GIOVANNI GABUTTI ET AL: "Booster Vaccination: The Role of Reduced Antigen Content Vaccines as a Preschool Booster", BIOMED RESEARCH INTERNATIONAL, vol. 60, no. 1, 1 January 2014 (2014-01-01), pages 13 - 10, XP055192849, ISSN: 2314-6133, DOI: 10.4103/0974-777X.77298 *
HILL ADRIAN V S: "Vaccines against malaria", PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON. SERIES B: BIOLOGICAL SCIENCES, ROYAL SOCIETY OF LONDON, LONDON, GB, vol. 366, no. 1579, 12 October 2011 (2011-10-12), pages 2806 - 2814, XP002700406, ISSN: 0080-4622, DOI: 10.1098/RSTB.2011.0091 *
L. C. PAOLETTI ET AL: "Effects of Alum Adjuvant or a Booster Dose on Immunogenicity during Clinical Trials of Group B Streptococcal Type III Conjugate Vaccines", INFECTION AND IMMUNITY, vol. 69, no. 11, 1 November 2001 (2001-11-01), pages 6696 - 6701, XP055208551, ISSN: 0019-9567, DOI: 10.1128/IAI.69.11.6696-6701.2001 *
STOUTE J A ET AL: "A PRELIMINARY EVALUATION OF A RECOMBINANT CIRCUMSPOROZOITE PROTEIN VACCINE AGAINST PLASMODIUM FALCIPARUM MALARIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 336, no. 2, 9 January 1997 (1997-01-09), pages 86 - 91, XP000990284, ISSN: 0028-4793, DOI: 10.1056/NEJM199701093360202 *
STOUTE J A ET AL: "LONG-TERM EFFICACY AND IMMUNE RESPONSES FOLLOWING IMMUNIZATION WITH THE RTS,S MALARIA VACCINE", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS, CHICAGO, IL, vol. 178, no. 4, 1 October 1998 (1998-10-01), pages 1139 - 1144, XP008046110, ISSN: 0022-1899, DOI: 10.1086/515657 *
W. R. BALLOU: "The development of the RTS,S malaria vaccine candidate: challenges and lessons", PARASITE IMMUNOLOGY, vol. 31, no. 9, 1 September 2009 (2009-09-01), pages 492 - 500, XP055208451, ISSN: 0141-9838, DOI: 10.1111/j.1365-3024.2009.01143.x *

Also Published As

Publication number	Publication date
JP6655549B2 (ja)	2020-02-26
EA037405B1 (ru)	2021-03-25
EP3125930A1 (en)	2017-02-08
SG11201607086QA (en)	2016-09-29
EP3125929B8 (en)	2023-12-27
US10624961B2 (en)	2020-04-21
CN106456738B (zh)	2021-06-29
MX2016012982A (es)	2016-12-07
JP2017511327A (ja)	2017-04-20
EP3125929C0 (en)	2023-11-01
AU2015239025B2 (en)	2018-01-25
BE1022355A1 (fr)	2016-02-16
CA2943007C (en)	2024-01-09
KR20230075525A (ko)	2023-05-31
KR102762440B1 (ko)	2025-02-03
MX2022013912A (es)	2022-12-13
AU2015239025A1 (en)	2016-09-22
MX2016012932A (es)	2016-12-07
CA2943007A1 (en)	2015-10-08
AR099960A1 (es)	2016-08-31
CN106456738A (zh)	2017-02-22
US11951161B2 (en)	2024-04-09
ES2961840T3 (es)	2024-03-14
CN106456739A (zh)	2017-02-22
JP2017511324A (ja)	2017-04-20
ZA201605955B (en)	2019-04-24
JP6645982B2 (ja)	2020-02-14
WO2015150568A1 (en)	2015-10-08
US20200306353A1 (en)	2020-10-01
KR20160132115A (ko)	2016-11-16
US20170112914A1 (en)	2017-04-27
EP3125929A1 (en)	2017-02-08
IL247493B (en)	2022-08-01
EP3125930B1 (en)	2020-12-02
GB201405921D0 (en)	2014-05-14
EA201691638A1 (ru)	2017-04-28
EP3125929B1 (en)	2023-11-01
US20170136110A1 (en)	2017-05-18
BR112016022787A2 (pt)	2018-03-27
ES2853773T3 (es)	2021-09-17
CA2943711A1 (en)	2015-10-08
WO2015150567A1 (en)	2015-10-08
US10688168B2 (en)	2020-06-23
BR112016022463A2 (pt)	2017-10-10
IL247493A0 (en)	2016-11-30

Legal Events

Date	Code	Title	Description
2019-12-19	MM	Lapsed because of non-payment of the annual fee	Effective date: 20190430

Publication	Publication Date	Title
BE1022355B1 (fr)	2016-03-26	Nouvelles méthodes d'induction d'une réponse immunitaire
JP5486802B2 (ja)	2014-05-07	抗マラリアワクチン
AP1166A (en)	2003-06-30	Vaccine composition against malaria.
CN110290806A (zh)	2019-09-27	用于诱导免疫应答的新型方法
BE1024188B1 (fr)	2017-12-14	Composition séchée
BE1022373B1 (fr)	2016-03-25	Nouveaux vaccins antipaludeens
BE1021315B1 (fr)	2015-10-28	Nouvelles compositions
BE1022950B1 (fr)	2016-10-21	Procedes d'induction d'une reponse immunitaire
WO2019243018A1 (fr)	2019-12-26	Composes peptidiques multiepitopiques et vaccins contre la leishmaniose
BE1022523B1 (fr)	2016-05-20	Vaccination
FR3014103B1 (fr)	2019-08-16	Composition vaccinale pour la prevention et/ou le traitement de leishmanioses, peptides immunogenes et procede d'obtention